NCT06045858View on ClinicalTrials.gov

Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions

Atrial FibrillationPeritoneal Dialysis Complication

Interventions

DRUG

Anticoagulation Agents

anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year

All Listed Sponsors

lead

University Hospital, Caen

OTHER

NCT06045858 - Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2) | Biotech Hunter | Biotech Hunter